Targeting faulty DNA repair in a type of leukemia with specific mutations
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AML
['FUNDING_R01'] · YALE UNIVERSITY · NIH-11014403
This study is looking at new ways to treat patients with acute myeloid leukemia who have specific gene mutations, aiming to find better combinations of existing drugs to help improve their treatment outcomes.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11014403 on ClinicalTrials.gov |
What this research studies
This research focuses on patients with acute myeloid leukemia (AML) who have mutations in the IDH1 and IDH2 genes. These mutations lead to the production of a harmful metabolite that disrupts normal cell function and contributes to the disease. The research aims to explore new treatment strategies that target the defective DNA damage response pathways caused by these mutations, potentially using existing drugs in novel combinations. By understanding how these mutations affect cancer cell behavior, the study seeks to improve treatment outcomes for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have specific mutations in the IDH1 or IDH2 genes.
Not a fit: Patients without IDH1/2 mutations or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with IDH1/2-mutant AML, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promising results in targeting DNA damage response pathways in cancer, suggesting that this approach could be effective for IDH1/2-mutant AML as well.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BINDRA, RANJIT — YALE UNIVERSITY
- Study coordinator: BINDRA, RANJIT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers